Boston Scientific Resumes Most, Not All, Implantable Defibrillator Shipments
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific resumed shipments of virtually all of its implantable defibrillators April 15 following retrospective clearance by FDA of two manufacturing changes
You may also be interested in...
Optimism On ICDs: St. Jude And Boston Scientific Exceed Expectations
St. Jude Medical reported strong cardiac rhythm management results in the second quarter and said it picked up market share, but struggling competitor Boston Scientific refused to recoil, announcing U.S. ICD sales losses that were about half what was expected
Optimism On ICDs: St. Jude And Boston Scientific Exceed Expectations
St. Jude Medical reported strong cardiac rhythm management results in the second quarter and said it picked up market share, but struggling competitor Boston Scientific refused to recoil, announcing U.S. ICD sales losses that were about half what was expected
Medtronic's Resolute Efficacy On Par With Abbott's Xience In One-Year Study
One-year efficacy results reported May 25 at the EuroPCR meeting in Paris could help Medtronic claim a bigger stake in the drug-eluting stent market, where Abbott and Boston Scientific have increasingly dominated